## Edgar Filing: Capstone Therapeutics Corp. - Form 4

Capstone T Form 4 February 13	herapeutics Corp.											
								OMB A	PPROVAL			
FORM	UNITED	STATES		RITIES A shington			E COMMISSIO	N OMB Number:	3235-02	287		
Check t if no lou subject Section Form 4 Form 5 obligati	nger to 16. or Filed put ons Section 17(	STATEMENT OF CHANGES SEC Filed pursuant to Section 16(a) Section 17(a) of the Public Utility				ties Excha	Estimated burden hoi response	Estimated average burden hours per response 0.5				
See Instruction 1(b). Solution See Instruction 1(b). Solution See Instruction 1(b). See Instruction 1(b). See Instruction 17(a) of the Public Utility Holding Company Act of 1935 or Section 17(a) of the Investment Company Act of 1940												
(Print or Type	Responses)											
1. Name and HOLLIMA	Symbol	er Name <b>an</b> ne Therar		r Trading orp. [CAP	5. Relationship of Reporting Person(s) to Issuer							
(Last)	(First) (	Middle)	3. Date of	eck all applicabl	k all applicable)							
1275 W. WASHINGTON STREET, SUITE 101			(Month/ 02/06/2	Day/Year) 2014			X Director 10% Owner X Officer (give title Other (specify below) below) Executive Chairman					
				endment, D onth/Day/Yea	-	al	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
TEMPE, A	Z 85281						Form filed by Person	More than One R	eporting			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned			
(Instr. 3) any		Execution	Date, if TransactionAcquired (A) or Code Disposed of (D) ay/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature o Indirect				
				Code V		(D) Price	(Instr. 3 and 4)					
Reminder: Re	eport on a separate line	e for each cl	ass of sec	urities bene	Perso infor requi	ons who res nation cont red to resp	or indirectly. spond to the collectained in this form ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)			

number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: Capstone Therapeutics Corp. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Y	Year) (	Instr. 8		Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
			(	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (Right to Buy)	\$ 0.3	02/06/2014		А		22,000		02/06/2014 <u>(1)</u>	02/06/2024	Common Stock	22,000

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
HOLLIMAN JOHN M III 1275 W. WASHINGTON STREET, SUITE 101 TEMPE, AZ 85281	Х		Executive Chairman				
Signatures							
/s/Les M Taeger Attorney							

in-fact 02/13/2014

\*\*Signature of Reporting Person

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) 50% to vest 2/6/2014 and 50% to vest monthly by 2/6/2015

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.